Amendments to the Specification

Please replace the paragraph at page 4, lines 3-10 (as amended in the Paper submitted on January 22, 2001) with the following paragraph:

--The construction of mutant virus 1716 is described in U.S. Patent No. 6,040,169, the entire contents of which is incorporated herein by reference. The mutant virus called 1716 has been deposited with the ECACC PHLS Center for Applied Microbiology and Research, Porton Down, Salisbury, Wits. SP4 PJG, UK, on January 28, 1992, under conditions of the Budapest Treaty, and has been assigned the Accession No. V92012803. However this patent publication is solely concerned with the use of mutant 1716 as a vaccine, either in itself or as a vector vaccine which includes a heterologous gene coding for an antigen.--